Are drug clinical trials broadly applicable? The case of staphylococcal bacteraemia

International Journal of Antimicrobial Agents
Yoav Keynan, Ethan Rubinstein

Abstract

Clinical trials are traditionally designed by pharmaceutical companies or clinical research organizations to address the requirements and regulations of national regulatory agencies such as the US Food and Drug Administration. The criteria for enrolment are strict and well-defined, necessitating the screening of large numbers of individuals for each subject enrolled. Common exclusion criteria include extremes of age and weight, pregnancy, previous treatment with effective antibiotics for the same infection, organ dysfunction, malignant diseases with a short survival time, advanced HIV etc. In clinical trials, cost, length of hospital stay, complexity of drug administration and patient and family preferences are rarely considered, and seldom make their way into the report of the trial. The limited patient population and under-representation of sicker, older individuals leads to underestimation of drug toxicity and overestimation of efficacy. Postmarketing studies are commonly used to document adverse reactions, but they are not supported by industry and receive limited funding. We chose to evaluate the applicability to general staphylococcal bacteraemia patient populations of clinical trials comparing antimicrobial agents used t...Continue Reading

References

Jun 5, 1999·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I RaadR Hachem
Oct 1, 2005·The Journal of Antimicrobial Chemotherapy·Andrew F ShorrMarin Kollef
Jun 27, 2006·BMJ : British Medical Journal·David H WyllieTim E A Peto
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Nov 7, 2007·Antimicrobial Agents and Chemotherapy·Sung-Han KimKang-Won Choe
Dec 17, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark H WilcoxCharles Knirsch
Feb 12, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveHelen W Boucher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.